Raymond James downgraded Zimmer Biomet (ZBH) to Market Perform from Outperform without a price target The firm is “frustrated” with the company’s inconsistent growth and believes this dynamic may persist in 2026. Zimmer’s revenue growth will remain challenged, and with its margins optimized, a slower revenue growth profile will temper earnings growth, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Evercore ISI upgrades four, downgrades six in MedTech and Tools
- Zimmer Biomet upgraded to Outperform from In Line at Evercore ISI
- The Week That Was, The Week Ahead: Macro & Markets, Dec. 28
- Zimmer Biomet: Solid Long-Term Setup but Execution Risks and Conservative Guidance Justify Hold Rating
- JPMorgan sees 2026 as ‘pivotal year’ for Zimmer Biomet